BioCardia (NASDAQ:BCDA – Get Free Report) is one of 844 public companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare BioCardia to related businesses based on the strength of its earnings, institutional ownership, profitability, dividends, valuation, analyst recommendations and risk.
Insider and Institutional Ownership
20.6% of BioCardia shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 17.4% of BioCardia shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Valuation and Earnings
This table compares BioCardia and its competitors top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| BioCardia | $60,000.00 | -$8.23 million | -1.44 |
| BioCardia Competitors | $691.13 million | $10.43 million | -10.02 |
BioCardia’s competitors have higher revenue and earnings than BioCardia. BioCardia is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Risk & Volatility
BioCardia has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500. Comparatively, BioCardia’s competitors have a beta of 1.14, suggesting that their average stock price is 14% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current ratings for BioCardia and its competitors, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioCardia | 1 | 1 | 1 | 0 | 2.00 |
| BioCardia Competitors | 9782 | 15053 | 45297 | 1571 | 2.54 |
BioCardia presently has a consensus price target of $25.00, indicating a potential upside of 2,612.67%. As a group, “Biotechnology” companies have a potential upside of 97.51%. Given BioCardia’s higher probable upside, analysts clearly believe BioCardia is more favorable than its competitors.
Profitability
This table compares BioCardia and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioCardia | N/A | -569.36% | -183.15% |
| BioCardia Competitors | -9,046.59% | -199.78% | -30.61% |
Summary
BioCardia competitors beat BioCardia on 9 of the 13 factors compared.
About BioCardia
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.
Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.
